MCID: PSR002
MIFTS: 64

Psoriasis

Categories: Rare diseases, Skin diseases, Genetic diseases

Aliases & Classifications for Psoriasis

MalaCards integrated aliases for Psoriasis:

Name: Psoriasis 12 50 24 29 52 41 3 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:8893
ICD10 33 L40 L40.9
MeSH 42 D011565
NCIt 47 C3346
UMLS 69 C0033860

Summaries for Psoriasis

MedlinePlus : 41 psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. you usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. some people who have psoriasis also get a form of arthritis called psoriatic arthritis. a problem with your immune system causes psoriasis. in a process called cell turnover, skin cells that grow deep in your skin rise to the surface. normally, this takes a month. in psoriasis, it happens in just days because your cells rise too fast. psoriasis can be hard to diagnose because it can look like other skin diseases. your doctor might need to look at a small skin sample under a microscope. psoriasis can last a long time, even a lifetime. symptoms come and go. things that make them worse include infections stress dry skin certain medicines psoriasis usually occurs in adults. it sometimes runs in families. treatments include creams, medicines, and light therapy. nih: national institute of arthritis and musculoskeletal and skin diseases

MalaCards based summary : Psoriasis is related to lymphoma and celiac disease, and has symptoms including exanthema, pruritus and psoriasiform rash. An important gene associated with Psoriasis is HLA-C (Major Histocompatibility Complex, Class I, C), and among its related pathways/superpathways are Keratinization and Interleukin-4 and 13 signaling. The drugs Rayos and Acitretin have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells.

NIH Rare Diseases : 50 psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. the skin on the elbows, knees, scalp, back, face, palms and feet is most often affected, but other parts of the body can be affected as well. a problem with the immune system causes psoriasis. in a process called cell turnover, skin cells that grow deep in the skin rise to the surface. normally, this takes a month. in psoriasis, it happens in just days because the cells rise too fast. although symptoms may come and go, for many, psoriasis is a lifelong condition. infections, stress, dry skin and certain medications may make symptoms worse. psoriasis usually occurs in adults. it sometimes runs in families. treatments include creams, medications and light therapy. last updated: 7/11/2016

CDC : 3 Psoriasis causes patches of thick red skin and silvery scales. Patches are typically found on the elbows, knees, scalp, lower back, face, palms, and soles of feet, but can affect other places (fingernails, toenails, and mouth). The most common type of psoriasis is called plaque psoriasis.Psoriatic arthritis is an inflammatory type of arthritis that eventually occurs in 10% to 20% of people with psoriasis. It is different from more common types of arthritis (such as osteoarthritis or rheumatoid arthritis) and is thought to be related to the underlying problem of psoriasis. Psoriasis and psoriatic arthritis are sometimes considered together as psoriatic disease.

Wikipedia : 72 Psoriasis is a long-lasting autoimmune disease which is characterized by patches of abnormal skin. These... more...

Related Diseases for Psoriasis

Diseases in the Psoriasis family:

Psoriasis 2

Diseases related to Psoriasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 464)
id Related Disease Score Top Affiliating Genes
1 lymphoma 31.0 CDSN IL17A TNF
2 celiac disease 30.4 CDSN HLA-C PSORS1C1 PSORS1C2
3 atherosclerosis 30.2 CCL2 IL17A MICA TNF
4 lung disease 30.2 IL17A TNF
5 neuropathy 29.8 FLG KRT16 TNF
6 psoriasis 14, pustular 12.4
7 psoriasis susceptibility 1 12.4
8 guttate psoriasis 12.3
9 pustular psoriasis 12.2
10 psoriatic arthritis 12.1
11 psoriasis susceptibility 13 12.1
12 psoriasis 2 12.1
13 psoriasis 15, pustular 12.0
14 psoriasis, protection against 12.0
15 pustulosis palmaris et plantaris 11.9
16 mental retardation and psoriasis 11.8
17 psoriatic juvenile idiopathic arthritis 11.5
18 tranebjaerg svejgaard syndrome 11.5
19 impetigo herpetiformis 11.4
20 pustulosis of palm and sole 11.2
21 arthritis 11.2
22 geographic tongue 11.1
23 parapsoriasis 11.1
24 subacute cutaneous lupus erythematosus 11.0
25 chronic recurrent multifocal osteomyelitis 11.0
26 hairy nose tip 11.0 CDSN HLA-C
27 pyridoxal 5'-phosphate-dependent epilepsy 11.0 CARD14 IL36RN TNF
28 combined oxidative phosphorylation deficiency 10.9 CCHCR1 CDSN PSORS1C1
29 anaerobic meningitis 10.9 HLA-C IL36RN TNF
30 neonatal marfan syndrome 10.9 IL17A IL36RN
31 orbital osteomyelitis 10.9 HLA-C IL17A TNF
32 cytomegalovirus disease in patients with impaired cell mediated immunity deemed at risk 10.8 CCL2 IL17A TNF
33 singleton-merten syndrome 1 10.8
34 systemic onset juvenile idiopathic arthritis 10.8
35 dermatosis papulosa nigra 10.8 IL36RN TNF
36 steatocystoma multiplex 10.8 KRT16 KRT17
37 ostertagiasis 10.8 CCL2 IL17A TNF
38 primary systemic mycosis 10.8 IL17A TNF
39 dicrocoeliasis 10.8 KRT16 KRT17
40 muscle tissue disease 10.8 HLA-C IL17A MICA TNF
41 ragweed sensitivity 10.8 CCL2 IL17A TNF
42 brucella canis brucellosis 10.8 AREG CDSN TNF
43 basal cell carcinoma 4 10.8 KRT16 KRT17
44 mesenchymal cell neoplasm 10.8 CCL2 IL17A TNF
45 leprosy 4 10.8 HLA-C IL17A MICA TNF
46 papilledema 10.8 KRT16 KRT17 TNF
47 optic nerve hypoplasia 10.8 CCL2 IL17A TNF
48 neonatal jaundice 10.7 CCL2 IL17A TNF
49 goodpasture syndrome 10.7 HLA-C IL17A MICA TNF
50 spontaneous ocular nystagmus 10.7 AREG IL17A TNF

Graphical network of the top 20 diseases related to Psoriasis:



Diseases related to Psoriasis

Symptoms & Phenotypes for Psoriasis

UMLS symptoms related to Psoriasis:


exanthema, pruritus, psoriasiform rash

Drugs & Therapeutics for Psoriasis

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Rayos 17 PREDNISONE Horizon Pharma July of 2012

Drugs for Psoriasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 410)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acitretin Approved Phase 4,Phase 3,Phase 2 55079-83-9 6437841 5284513
2
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 185243-69-0
3
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
5
Ustekinumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 815610-63-0
6
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
7
Adalimumab Approved Phase 4,Phase 2,Phase 3,Phase 1 331731-18-1 16219006
8
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 5271565 637568
9
Zinc Approved Phase 4,Phase 3 7440-66-6 32051 23994
10
Infliximab Approved Phase 4,Phase 3,Phase 2 170277-31-3
11
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
12
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 378-44-9 9782
13
Desoximetasone Approved Phase 4,Phase 3,Phase 2 382-67-2 5311067
14
Apremilast Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 608141-41-9 11561674
15
Anthralin Approved Phase 4 1143-38-0
16
Tazarotene Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 118292-40-3 5381
17
Clocortolone Approved Phase 4 34097-16-0, 4828-27-7 5282493 5311052
18
Acetaminophen Approved Phase 4 103-90-2 1983
19
Guaifenesin Approved, Vet_approved Phase 4,Phase 2,Phase 1 93-14-1 3516
20
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
21
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
22
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
23 Racepinephrine Approved Phase 4,Phase 2
24
Triamcinolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 124-94-7 31307
25
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
26
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
27
Dapsone Approved, Investigational Phase 4 80-08-0 2955
28
Desonide Approved, Investigational Phase 4 638-94-8 5311066
29
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
30
Capsaicin Approved Phase 4 404-86-4 1548943
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
32
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
33 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
34
Calcitriol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 32222-06-3 134070 5280453
35
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1406-16-2
36
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
37
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3 59-67-6 938
38
Nicotinamide Approved, Nutraceutical Phase 4,Phase 2,Phase 3 98-92-0 936
39
Clobetasol Investigational Phase 4,Phase 2,Phase 3,Phase 1 25122-46-7, 25122-41-2 32798 5311051
40
Butyric Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1 107-92-6 264
41 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Keratolytic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
44 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
45 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
47 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
48 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
49 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1334)

id Name Status NCT ID Phase Drugs
1 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis Unknown status NCT01223976 Phase 4
2 Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2 Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
3 Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate Unknown status NCT02313922 Phase 4 etanercept combined with methotrexate or etanercept combined with placebo
4 Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis Unknown status NCT02144857 Phase 4 etanercept;ustekinumab;cyclosporine
5 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis Unknown status NCT01439425 Phase 4
6 Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
7 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
8 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
9 Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
10 A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
11 The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
12 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
13 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
14 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
15 Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
16 An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis Completed NCT01555606 Phase 4
17 Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis Completed NCT00195507 Phase 4 Etanercept
18 Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis Completed NCT00924950 Phase 4 Taclonex Ointment and Hydrogel Patch;Taclonex Ointment
19 A Study of Efalizumab in Patients With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies Completed NCT00249808 Phase 4 Efalizumab - anti CD11a recombinant human monoclonal antibody
20 A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries Completed NCT01677598 Phase 4 No intervention
21 Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis Completed NCT01012713 Phase 4 Clobex Spray;Vectical Ointment
22 A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis Completed NCT01373567 Phase 4 TINEFCON
23 Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis Completed NCT00990561 Phase 4 Ultravate ointment twice daily + LacHydrin lotion twice daily;Ultravate ointment once daily + LacHydrin lotion twice daily
24 A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis Completed NCT00852761 Phase 4 Olux-E Foam;Clobex lotion
25 Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis Completed NCT01039142 Phase 4 Acitretin
26 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept
27 Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Completed NCT00992394 Phase 4 etanercept;etanercept
28 Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray Completed NCT02985736 Phase 4 Topicort Topical Spray
29 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
30 A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis. Completed NCT01262534 Phase 4
31 Topical Psoriasis Study for Patients Receiving Biologic Therapy Completed NCT02983981 Phase 4 Topicort Topical Spray
32 The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment Completed NCT01511315 Phase 4 Ustekinumab
33 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
34 Clinical Assessment and Psychosocial Impact of Psoriasis Completed NCT01964443 Phase 4
35 A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp Completed NCT00669214 Phase 4 efalizumab;placebo
36 Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis Completed NCT00936065 Phase 4 Etanercept;Etanercept + Acitretin;Acitretin
37 Moderate to Severe Plaque Psoriasis With Scalp Involvement Completed NCT00791765 Phase 4
38 Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis Completed NCT00110981 Phase 4 Etanerept;Etanercept
39 Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects Completed NCT00658606 Phase 4 alefacept
40 Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis Completed NCT01265823 Phase 4
41 Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp Completed NCT00881868 Phase 4 clobetasol propionate spray 0.05%;Vehicle spray
42 Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis Completed NCT00161655 Phase 4 Etanercept;Methotrexate
43 Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet Completed NCT00735787 Phase 4
44 Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy Completed NCT00581555 Phase 4 Etanercept
45 Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis Completed NCT00655564 Phase 4 Alefacept
46 Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in Psoriasis Completed NCT00332332 Phase 4
47 Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings Completed NCT00708708 Phase 4 etanercept (Enbrel®)
48 Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis Completed NCT00723437 Phase 4 acitretin
49 Adalimumab-psoriasis and Small Bowel Lesions Completed NCT01556672 Phase 4 Adalimumab
50 Narrow-Band UVB-Therapy in Psoriasis Completed NCT00748020 Phase 4

Search NIH Clinical Center for Psoriasis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Psoriasis

Genetic tests related to Psoriasis:

id Genetic test Affiliating Genes
1 Psoriasis 29 24

Anatomical Context for Psoriasis

MalaCards organs/tissues related to Psoriasis:

39
Skin, Testes, T Cells, Endothelial, Liver, Neutrophil, Bone

Publications for Psoriasis

Articles related to Psoriasis:

(show top 50) (show all 3215)
id Title Authors Year
1
Generalized Pustular Psoriasis With IL-36 Receptor Antagonist Mutation Successfully Treated With Granulocyte and Monocyte Adsorption Apheresis Accompanied by Reduced Serum IL-6 Level. ( 28913961 )
2017
2
Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series. ( 28932788 )
2017
3
Recalcitrant infantile generalized pustular psoriasis successfully treated with acitretin and narrowband ultraviolet B. ( 28106270 )
2017
4
Bullous pemphigoid with IgG autoantibodies to the I+3 subunit of laminin 332 associated with psoriasis vulgaris. ( 28468743 )
2017
5
Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis. ( 28069297 )
2017
6
Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis. ( 28954122 )
2017
7
TWEAK mediates inflammation in experimental atopic dermatitis and psoriasis. ( 28530223 )
2017
8
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). ( 28074446 )
2017
9
Autosomal dominant familial generalized pustular psoriasis caused by a CARD14 mutation. ( 28295164 )
2017
10
Granulocyte and monocyte apheresis can control juvenile generalised pustular psoriasis with mutation of the IL36RN gene. ( 28369922 )
2017
11
Tailored Therapist-guided Internet-based Cognitive-behavioural Treatment for Psoriasis and Rheumatoid Arthritis: Two Case Reports. ( 28952654 )
2017
12
Cyr61/CCN1 is involved in the pathogenesis of psoriasis vulgaris via promoting IL-8 production by keratinocytes in a JNK/NF-I_B pathway. ( 27856305 )
2017
13
Relapsing polychondritis associated with psoriasis vulgaris successfully treated with adalimumab: A case report with published work review. ( 28266051 )
2017
14
Follicular Psoriasis: Differentiation from Pityriasis Rubra Pilaris-An Illustrative Case and Review of the Literature. ( 27874201 )
2017
15
CD40 Ligand Is Increased in Mast Cells in Psoriasis and Actinic Keratosis but Less So in Epithelial Skin Carcinomas. ( 28267402 )
2017
16
Pityriasis Lichenoides et Varioliformis Acuta and Psoriasis Vulgaris: Mere Coincidence or a Rare Association? ( 28218230 )
2017
17
Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa. ( 28917381 )
2017
18
Improvement of the initial stage of interstitial lung disease during psoriasis treatment with secukinumab. ( 28891081 )
2017
19
Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients. ( 28496328 )
2017
20
Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis. ( 28527093 )
2017
21
The role of IL-4 in psoriasis. ( 28064550 )
2017
22
Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT. ( 28076860 )
2017
23
Investigation of the clinical features of geographic tongue: unveiling its relationship with oral psoriasis. ( 28188609 )
2017
24
Generalized pustular psoriasis: A possible association with severe hypocalcaemia due to primary hypoparathyroidism. ( 28106254 )
2017
25
Usefulness of dual-energy computed tomography for the evaluation of early-stage psoriatic arthritis only accompanied by nail psoriasis. ( 28836684 )
2017
26
Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis. ( 27864793 )
2017
27
Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy. ( 28280914 )
2017
28
A preliminary study of new single polymorphisms in the T helper type 17 pathway for psoriasis in the Korean population. ( 27774581 )
2017
29
Subclinical enthesopathy in patients with psoriasis and its association with other disease parameters: a power Doppler ultrasonographic study. ( 28293449 )
2017
30
Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: a systematic literature review. ( 28521047 )
2017
31
Acquired hemophilia A following generalized pustular psoriasis of pregnancy. ( 28771773 )
2017
32
Guttate psoriasis triggered by perianal streptococcal infection. ( 28543851 )
2017
33
Psoriasis and Cardiovascular Risk-Do Promising New Biomarkers Have Clinical Impact? ( 28947858 )
2017
34
Case of generalized pustular psoriasis presenting with both pleural effusion and pericardial effusion collection. ( 28636215 )
2017
35
Toll-like receptor (TLR)7 expression in mycosis fungoides and psoriasis: a case-control study. ( 28054376 )
2017
36
Hypomethylation of HLA-DRB1 and its clinical significance in psoriasis. ( 27713139 )
2017
37
Comparison of psoriasis and atopic dermatitis guidelines-an argument for aggressive atopic dermatitis management. ( 28944965 )
2017
38
Two Cases of Successful Treatment of Refractory Chronic Inflammatory Skin Disease, Atopic Dermatitis and Psoriasis with Oral Alitretinoin. ( 28761307 )
2017
39
Association of Generalized Psoriasis and Mixed Glomerulonephritis in a 10-year-old Girl. ( 28871929 )
2017
40
Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus. ( 28940579 )
2017
41
A case of erythema multiforme drug eruption associated with erythrodermic psoriasis induced by sofosbuvir and daclatasvir. ( 27757979 )
2017
42
Kaposi's sarcoma concealed by stasis dermatitis in a patient with psoriasis. ( 28941266 )
2017
43
Acute Generalized Erythrodermic Pustular Psoriasis Associated with Bupropion/Naltrexone (Contrave(Ar)). ( 28130024 )
2017
44
Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis - Reply. ( 28954123 )
2017
45
A newly revealed IL36RN mutation in sibling cases complements our IL36RN mutation statistics for generalized pustular psoriasis. ( 27802907 )
2017
46
Proinflammatory effect of high-mobility group protein B1 onA keratinocytes: an autocrine mechanism underlying psoriasis development. ( 27859256 )
2017
47
T helper-2 cytokine/regulatory T-cell gene polymorphisms and their relation with risk of psoriasis in a South Indian Tamil cohort. ( 28027921 )
2017
48
The Impact of Age on Psoriasis Health Care in Germany. ( 28079929 )
2017
49
Melanocytes: Target Cells of an HLA-C*06:02-Restricted Autoimmune Response in Psoriasis. ( 28941475 )
2017
50
Isogarcinol Extracted from Garcinia mangostana L. Ameliorates Imiquimod-Induced Psoriasis-like Skin Lesions in Mice. ( 28081600 )
2017

Variations for Psoriasis

Copy number variations for Psoriasis from CNVD:

7 (show all 27)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 107130 17 1225928 31649829 Copy number CCL3L3 Psoriasis
2 107139 17 1225928 31649843 Copy number CCL3L1 Psoriasis
3 107160 17 1242109 31665953 Copy number CCL4L2 Psoriasis
4 110229 17 31562580 31665959 Copy number CCL4L1 Psoriasis
5 209406 6 2614953 31491069 Copy number MICA Psoriasis
6 211355 6 32593131 32665540 Copy number HLA-DRB5 Psoriasis
7 212281 6 3674895 32665540 Copy number HLA-DRB1 Psoriasis
8 212427 6 3795995 32719407 Copy number HLA-DQA1 Psoriasis
9 212447 6 3813334 32742444 Copy number HLA-DQB1 Psoriasis
10 230703 8 1 12700000 Copy number Psoriasis
11 241415 8 6200000 12700000 Copy number Psoriasis
12 241416 8 6200000 12700000 Copy number DEFB103 Psoriasis
13 241417 8 6200000 12700000 Copy number DEFB104 Psoriasis
14 241418 8 6200000 12700000 Copy number DEFB4 Psoriasis
15 241438 8 6200000 12700000 Gain DEFB103 Psoriasis
16 241439 8 6200000 12700000 Gain DEFB104 Psoriasis
17 241440 8 6200000 12700000 Gain DEFB105 Psoriasis
18 241441 8 6200000 12700000 Gain DEFB106 Psoriasis
19 241442 8 6200000 12700000 Gain DEFB107 Psoriasis
20 241443 8 6200000 12700000 Gain DEFB4 Psoriasis
21 241446 8 6200000 12700000 Gain SPAG11 Psoriasis
22 241447 8 6200000 12700000 High copy numbers Psoriasis
23 241468 8 6200000 12700000 Copy number DEFB4 Psoriasis
24 242595 8 7292685 7758729 Large repeat SPAG11 Psoriasis
25 242629 8 7327435 7723985 Large repeat DEFB106 Psoriasis
26 242645 8 7332652 7718770 Large repeat DEFB105 Psoriasis
27 242649 8 7340777 7710648 Large repeat DEFB107 Psoriasis

Expression for Psoriasis

LifeMap Discovery
Genes differentially expressed in tissues of Psoriasis patients vs. healthy controls: 35 (show all 41)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 S100A9 S100 calcium binding protein A9 Skin + 7.14 0.000
2 S100A7 S100 calcium binding protein A7 Skin + 7.06 0.000
3 S100A7A S100 calcium binding protein A7A Skin + 6.53 0.000
4 S100A8 S100 calcium binding protein A8 Skin + 6.48 0.000
5 SPRR2F small proline-rich protein 2F Skin + 6.27 0.000
6 PI3 peptidase inhibitor 3, skin-derived Skin + 6.19 0.000
7 KRT6C keratin 6C, type II Skin + 5.98 0.000
8 SPRR2A small proline-rich protein 2A Skin + 5.97 0.000
9 KRT6A keratin 6A, type II Skin + 5.90 0.000
10 SPRR2B small proline-rich protein 2B Skin + 5.41 0.000
11 KRT6B keratin 6B, type II Skin + 5.39 0.000
12 SPRR2D small proline-rich protein 2D Skin + 5.35 0.000
13 SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 Skin + 5.23 0.000
14 GJB2 gap junction protein, beta 2, 26kDa Skin + 4.97 0.000
15 SPRR2C small proline-rich protein 2C (pseudogene) Skin + 4.90 0.000
16 C10orf99 chromosome 10 open reading frame 99 Skin + 4.46 0.000
17 LCE3D late cornified envelope 3D Skin + 4.42 0.000
18 SPRR1A small proline-rich protein 1A Skin + 4.34 0.000
19 LCE3A late cornified envelope 3A Skin + 4.34 0.000
20 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) Skin + 4.33 0.000
21 SPRR1B small proline-rich protein 1B Skin + 4.29 0.000
22 KRT16 keratin 16, type I Skin + 4.27 0.000
23 KYNU kynureninase Skin + 4.26 0.000
24 LCN2 lipocalin 2 Skin + 4.20 0.000
25 SPRR2G small proline-rich protein 2G Skin + 4.12 0.000
26 LCE3E late cornified envelope 3E Skin + 4.12 0.000
27 SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 Skin + 3.97 0.000
28 FABP5 fatty acid binding protein 5 (psoriasis-associated) Skin + 3.89 0.000
29 IFI27 interferon, alpha-inducible protein 27 Skin + 3.80 0.000
30 TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) Skin + 3.73 0.000
31 FABP5P2 fatty acid binding protein 5 pseudogene 2 Skin + 3.72 0.000
32 KLK6 kallikrein-related peptidase 6 Skin + 3.54 0.000
33 IL36G interleukin 36, gamma Skin + 3.50 0.000
34 DEFB103B defensin, beta 103B Skin + 3.46 0.000
35 PAMR1 peptidase domain containing associated with muscle regeneration 1 Skin - 3.43 0.000
36 GJB6 gap junction protein, beta 6, 30kDa Skin + 3.38 0.000
37 SPRR2E small proline-rich protein 2E Skin + 3.24 0.000
38 POSTN periostin, osteoblast specific factor Skin - 3.14 0.000
39 CD36 CD36 molecule (thrombospondin receptor) Skin + 3.12 0.000
40 IGFL1 IGF-like family member 1 Skin + 3.11 0.000
41 CACNA1H calcium channel, voltage-dependent, T type, alpha 1H subunit Skin - 3.11 0.000
Search GEO for disease gene expression data for Psoriasis.

Pathways for Psoriasis

GO Terms for Psoriasis

Cellular components related to Psoriasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 AREG CCL2 IL17A IL20 IL36RN MICA

Biological processes related to Psoriasis according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.85 CCL2 HLA-C IL17A IL36RN TNF
2 inflammatory response GO:0006954 9.77 CCL2 IL17A IL36RN KRT16 TNF
3 response to glucocorticoid GO:0051384 9.61 AREG CCL2 TNF
4 cornification GO:0070268 9.56 CDSN FLG KRT16 KRT17
5 humoral immune response GO:0006959 9.5 CCL2 TNF TRAF3IP2
6 establishment of skin barrier GO:0061436 9.49 FLG KRT16
7 positive regulation of monocyte chemotaxis GO:0090026 9.48 CCL2 S100A7
8 positive regulation of hair follicle development GO:0051798 9.4 KRT17 TNF
9 positive regulation of osteoclast differentiation GO:0045672 9.33 IL17A IL20 TNF
10 keratinocyte differentiation GO:0030216 9.26 CDSN FLG KRT16 S100A7
11 epidermis development GO:0008544 9.02 CDSN FABP5 KRT16 KRT17 S100A7

Molecular functions related to Psoriasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transition metal ion binding GO:0046914 9.13 FLG S100A7 S100A7A
2 cytokine activity GO:0005125 9.1 AREG CCL2 IL17A IL20 IL36RN TNF

Sources for Psoriasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....